FRI0420 Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis

X Baraliakos,J Sieper,K Radford,R Landewe,D Baeten,J Braun,J Van Laar,F Vandenhende,D Van Der Heijde,P Wordsworth,H Kellner,B Borah,P Emery,D Laurent,W Hueber,A Wright,I Mcinnes,J Wollenhaupt

doi:10.1136/annrheumdis-2013-eular.1547

FRI0420 Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis

X Baraliakos, J Sieper + Show 16 more

https://doi.org/10.1136/annrheumdis-2013-eular.1547

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2013

Affiliation: Rheumazentrum Ruhrgebiet, Novartis (Switzerland), University of Amsterdam, Leiden University Medical Center, Nuffield Orthopaedic Centre, University of Leeds, University of Glasgow, Schön Klinik Hamburg Eilbek

#Active Ankylosing Spondylitis #Fatty Lesions + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundSecukinumab (fully human IgG1k anti-IL17A monoclonal antibody) significantly improved clinical signs and symptoms of active ankylosing spondylitis (AS) patients enrolled in a recent proof-of-concept (PoC) study. Magnetic resonance images (MRI)...

Full Text